This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

21 Most Volatile Biopharma Stocks Closing Out 2012

Celsion (CLSN): Top-line results from the phase III trial of Thermodox in liver cancer expected before the end of the year. The "HEAT" study compares Thermodox plus radiofrequency thermal ablation (RFA) versus RFA alone in patients with primary liver cancer. The primary endpoint of the study is improvement in progression-free survival.

Clovis Oncology (CLVS): Top-line results from a phase III study of CO-011 in pancreatic cancer expected before year's end. The "LEAP" study compares CO-011 versus gemcitabine in metastatic, chemo-naive pancreatic cancer patients whose tumors express low levels of hENT1, a protein which gemcitabine requires to enter cells. Survival is the study's primary endpoint.

Dynavax (DVAX) brings its hepatitis B vaccine Heplisav in front of an FDA advisory panel on Nov. 14.

FDA will announce an approval decision for Exelixis' (EXEL) medullary thyroid cancer drug cabozantinib on or before Nov. 29.

Gilead Sciences (GILD) presents important new data on its all-oral hepatitis C combination regimens at the American Association for the Study of Liver Disease annual meeting beginning Saturday, Nov. 10.

An FDA advisory panel convenes Dec. 20 to review Hemispherx Biopharma's (HEB) Ampligen as a treatment for chronic fatigue syndrome.

Nektar Therapeutics (NKTR) will release results from a phase III studies of NKTR-118 in opioid-induced constipation before the end of the year. The "KODIAC" trials, consisting of two phase III placebo-controlled efficacy and an open-label, placebo-controlled long-term safety study, are designed to determine the efficacy and safety of NKTR-118, a once-daily tablet, for the treatment of constipation in patients taking prescription opioid medications.

NPS Pharmaceuticals (NPSP) is expecting an FDA approval decision for Gattex on Friday, Dec. 28. Gattex treats patients with short-bowel syndrome. An FDA advisory panel voted last month to recommend the drug's approval.

Pfizer (PFE) awaits an FDA decision on Nov. 21 for tofacitinib, the first rheumatoid arthritis pill.

Vical (VICL): Top-line results before the end of the year for the phase III melanoma study of Allovectin (injected directly into melanoma lesions) versus dacarbazine or temozolomide in patients with recurrent metastatic melanoma. The primary endpoint of the study is durable response rate at 24 weeks but the more important and necessary (for approval) secondary endpoint is overall survival.

Vivus (VVUS) reports third-quarter financial results on Tuesday, Nov. 6, including the first reported sales for its weight-los pill Qsymia.

Ziopharm (ZIOP) set to announced results from the phase III study of palifosfamide in sarcoma. The "PICASSO III" study compares palifosfamide plus doxorubicin to doxorubicin alone in patients with front-line metastatic soft-tissue sarcoma. The study's primary endpoint is improvement in progression-free survival (for accelerated approval) and overall survival (for full approval.)

Sources: TheStreet research; BioMedTracker, a provider of independent research on biotechnology and pharmaceutical developments; and company and analyst reports.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,777.92 -0.23 -0.00%
S&P 500 2,063.95 +2.72 0.13%
NASDAQ 4,755.6560 +7.26 0.15%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs